These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series. Wibbeler E; Wang R; Reyes EL; Specchio N; Gissen P; Guelbert N; Nickel M; Schwering C; Lehwald L; Trivisano M; Lee L; Amato G; Cohen-Pfeffer J; Shediac R; Leal-Pardinas F; Schulz A J Child Neurol; 2021 May; 36(6):468-474. PubMed ID: 33356800 [TBL] [Abstract][Full Text] [Related]
4. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2. Lewis G; Morrill AM; Conway-Allen SL; Kim B J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868 [TBL] [Abstract][Full Text] [Related]
5. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa. Schaefers J; van der Giessen LJ; Klees C; Jacobs EH; Sieverdink S; Dremmen MHG; Spoor JKH; van der Ploeg AT; van den Hout JMP; Huidekoper HH Orphanet J Rare Dis; 2021 May; 16(1):221. PubMed ID: 33990214 [TBL] [Abstract][Full Text] [Related]
6. Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy. Specchio N; Pietrafusa N; Trivisano M Ther Clin Risk Manag; 2020; 16():213-222. PubMed ID: 32280231 [TBL] [Abstract][Full Text] [Related]
7. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort. Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Schulz A; Specchio N; de Los Reyes E; Gissen P; Nickel M; Trivisano M; Aylward SC; Chakrapani A; Schwering C; Wibbeler E; Westermann LM; Ballon DJ; Dyke JP; Cherukuri A; Bondade S; Slasor P; Cohen Pfeffer J Lancet Neurol; 2024 Jan; 23(1):60-70. PubMed ID: 38101904 [TBL] [Abstract][Full Text] [Related]
9. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Gutić M; Milosavljević MN; Safiye T; Milidrag A; Jankovic SM Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):561-570. PubMed ID: 36994735 [TBL] [Abstract][Full Text] [Related]
10. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. de Los Reyes E; Lehwald L; Augustine EF; Berry-Kravis E; Butler K; Cormier N; Demarest S; Lu S; Madden J; Olaya J; See S; Vierhile A; Wheless JW; Yang A; Cohen-Pfeffer J; Chu D; Leal-Pardinas F; Wang RY Pediatr Neurol; 2020 Sep; 110():64-70. PubMed ID: 32684372 [TBL] [Abstract][Full Text] [Related]
12. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report. Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290 [TBL] [Abstract][Full Text] [Related]
13. Early Symptoms and Treatment Outcomes in Neuronal Ceroid Lipofuscinosis Type 2: Croatian Experience. Radić Nišević J; Kolić I; Kostanjski M; Kovačević F; Prpić I J Pers Med; 2024 Jul; 14(8):. PubMed ID: 39201975 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878 [TBL] [Abstract][Full Text] [Related]
15. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2). Gissen P; Specchio N; Olaye A; Jain M; Butt T; Ghosh W; Ruban-Fell B; Griffiths A; Camp C; Sisic Z; Schwering C; Wibbeler E; Trivisano M; Lee L; Nickel M; Mortensen A; Schulz A Orphanet J Rare Dis; 2021 May; 16(1):217. PubMed ID: 33980287 [TBL] [Abstract][Full Text] [Related]
16. Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment. Mortensen A; Raebel EM; Wiseman S Orphanet J Rare Dis; 2022 Jan; 17(1):19. PubMed ID: 35045884 [TBL] [Abstract][Full Text] [Related]
17. Cerliponase Alfa: First Global Approval. Markham A Drugs; 2017 Jul; 77(11):1247-1249. PubMed ID: 28589525 [TBL] [Abstract][Full Text] [Related]
18. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. Schulz A; Ajayi T; Specchio N; de Los Reyes E; Gissen P; Ballon D; Dyke JP; Cahan H; Slasor P; Jacoby D; Kohlschütter A; N Engl J Med; 2018 May; 378(20):1898-1907. PubMed ID: 29688815 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE F1000Res; 2021; 10():614. PubMed ID: 35106137 [TBL] [Abstract][Full Text] [Related]
20. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Nickel M; Simonati A; Jacoby D; Lezius S; Kilian D; Van de Graaf B; Pagovich OE; Kosofsky B; Yohay K; Downs M; Slasor P; Ajayi T; Crystal RG; Kohlschütter A; Sondhi D; Schulz A Lancet Child Adolesc Health; 2018 Aug; 2(8):582-590. PubMed ID: 30119717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]